Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADRIAN RODRIGUEZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1952458846
CMS profile
134354
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$75,764.53

330 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 7; records 201–250 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADRIAN RODRIGUEZ

NPI 1952458846 · CMS profile ID 134354

Allopathic & Osteopathic Physicians / Dermatology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 7; records 201–250 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952458846?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADRIAN RODRIGUEZ, NPI 1952458846, CMS profile ID 134354. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952458846?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ADRIAN RODRIGUEZ, NPI 1952458846, CMS profile ID 134354. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952458846?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ADRIAN RODRIGUEZ, NPI 1952458846, CMS profile ID 134354, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1952458846?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

330 matching records · $75,764.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 330 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 330.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ortho Dermatologics, a division of Bausch Health US, LLC $7.8104/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684600205 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $1.8504/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684600207 CMS
Lilly USA, LLC $1,125.0004/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657648751 CMS
Lilly USA, LLC $1,800.0004/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651095 CMS
Lilly USA, LLC $1,800.0004/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657649887 CMS
Lilly USA, LLC $1,800.0004/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651093 CMS
Mayne Pharma Inc. $14.9704/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705517505 CMS
LEO Pharma Inc. $6.0003/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687270527 CMS
PFIZER INC. $0.7003/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673110295 CMS
PFIZER INC. $15.1903/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673115391 CMS
Lilly USA, LLC $4.7803/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657648749 CMS
Lilly USA, LLC $89.4203/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657649889 CMS
Lilly USA, LLC $23.5603/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651091 CMS
AbbVie, Inc. $24.3903/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647991377 CMS
Almirall LLC $17.2903/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676669581 CMS
PFIZER INC. $1.3003/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673113253 CMS
Janssen Scientific Affairs, LLC $2,800.0003/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657605545 CMS
Mylan Pharmaceuticals Inc. $13.5803/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694779807 CMS
Mayne Pharma Inc. $17.0303/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705517499 CMS
PFIZER INC. $13.9003/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673109571 CMS
Lilly USA, LLC $1,800.0003/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657648747 CMS
Lilly USA, LLC $1,800.0003/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657649885 CMS
Lilly USA, LLC $675.0003/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651089 CMS
Lilly USA, LLC $675.0003/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651265 CMS
UCB, Inc. $1,120.0003/18/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688233253 CMS
Janssen Scientific Affairs, LLC $28.2503/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657605539 CMS
Janssen Scientific Affairs, LLC $46.7103/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657605541 CMS
Janssen Scientific Affairs, LLC $34.9403/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657605543 CMS
Janssen Scientific Affairs, LLC $746.4503/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657605535 CMS
Janssen Scientific Affairs, LLC $110.0503/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657605537 CMS
LEO Pharma Inc. $4.5303/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687270525 CMS
PFIZER INC. $2.5103/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673114049 CMS
PFIZER INC. $1.9603/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673116303 CMS
Sensus Healthcare, Inc. $11.5303/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637748759 CMS
Celgene Corporation $18.2603/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672757713 CMS
Lilly USA, LLC $98.8203/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651959 CMS
Lilly USA, LLC $88.1303/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657647651 CMS
Lilly USA, LLC $19.8303/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651651 CMS
Lilly USA, LLC $3.2003/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651965 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.3603/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684600203 CMS
Novartis Pharmaceuticals Corporation $24.6303/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659755395 CMS
PFIZER INC. $3.6303/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673115923 CMS
UCB, Inc. $8.5503/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688378155 CMS
UCB, Inc. $19.7203/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688235235 CMS
UCB, Inc. $31.0003/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688235237 CMS
UCB, Inc. $5.4103/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688235239 CMS
UCB, Inc. $8.1303/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688235241 CMS
UCB, Inc. $5,000.0003/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688342743 CMS
UCB, Inc. $14.9603/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688381113 CMS
Lilly USA, LLC $16.4203/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651961 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $75,764.53 330
PY2020 $66,272.42 171
PY2021 $57,291.11 167
PY2022 $147,912.43 301
PY2023 $248,647.93 405
PY2024 $257,522.23 433
PY2025 $259,996.12 389

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $295,872.37 44
PY2024 Recipient $4,706.54 1
PY2024 Principal investigator $193,876.00 101
PY2023 Principal investigator $22,911.00 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $9,192.00 12/25/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175429513
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,392.50 12/18/2025 Non-covered Recipient Entity
Adrian O Rodriguez
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430632
Principal investigator 1 Eli Lilly and Company $8,210.00 11/21/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187873217
Principal investigator 1 Novartis Pharmaceuticals Corporation $84.16 11/15/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190313179
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,473.75 11/13/2025 Non-covered Recipient Entity
Adrian O Rodriguez
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430630
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,500.00 11/06/2025 Non-covered Recipient Entity
Adrian O Rodriguez
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430628
Principal investigator 1 Janssen Research & Development, LLC $4,572.00 10/24/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175429524
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,626.88 10/23/2025 Non-covered Recipient Entity
Adrian O Rodriguez
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430626
Principal investigator 1 Janssen Research & Development, LLC $1,540.00 09/29/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175429494
Principal investigator 1 Janssen Research & Development, LLC $5,599.00 09/08/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175429500
Principal investigator 1 Janssen Research & Development, LLC $16,017.00 07/31/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175429506
Principal investigator 1 LEO Pharma AS $910.00 07/18/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB No dispute reported 06/30/2026 1251993549
Principal investigator 1 LEO Pharma AS $676.00 07/18/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB No dispute reported 06/30/2026 1251993553
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273183
Principal investigator 1 Janssen Research & Development, LLC $260.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273468
Principal investigator 1 Janssen Research & Development, LLC $1,947.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273623
Principal investigator 1 Janssen Research & Development, LLC $1,947.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273659
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273819
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273827
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273836
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274202
Principal investigator 1 Janssen Research & Development, LLC $1,947.00 06/20/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274239
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273300
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273525
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273705
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274136
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274316
Principal investigator 1 Janssen Research & Development, LLC $13,550.00 05/29/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175429519
Principal investigator 1 Janssen Research & Development, LLC $2,381.00 04/28/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273501
Principal investigator 1 Janssen Research & Development, LLC $201.00 03/25/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273346
Principal investigator 1 Janssen Research & Development, LLC $201.00 03/25/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273928
Principal investigator 1 Janssen Research & Development, LLC $201.00 03/25/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274245
Principal investigator 1 Janssen Research & Development, LLC $201.00 03/25/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274478
Principal investigator 1 Janssen Research & Development, LLC $2,381.00 03/24/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273645
Principal investigator 1 Janssen Research & Development, LLC $3,239.00 03/24/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273802
Principal investigator 1 Janssen Research & Development, LLC $3,537.00 03/24/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274549
Principal investigator 1 Janssen Research & Development, LLC $2,381.00 02/27/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273220
Principal investigator 1 Janssen Research & Development, LLC $2,359.00 02/27/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273920
Principal investigator 1 Janssen Research & Development, LLC $1,299.00 02/27/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274066
Principal investigator 1 Janssen Research & Development, LLC $3,537.00 02/27/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175274488
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,708.08 02/01/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190313181
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 01/27/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273616
Principal investigator 1 Janssen Research & Development, LLC $1,299.00 01/27/2025 Non-covered Recipient Entity
Advanced Rsrch Experts Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175273846
Principal investigator 1 Eli Lilly and Company $154,681.00 01/08/2025 Non-covered Recipient Entity
ADVANCED RESEARCH EXPERTS PLLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187874135